[1]CHU V C, MCELORY L J, CHU V, et al. The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells[J]. Virol, 2006, 80: 3180-3188.[2]BIJLENGA G, COOK J K, GELB J, et al. Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review[J]. Avian Pathol, 2004, 33: 550-557.[3]CAVANGH D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus[J]. Avian Pathol, 2003, 32: 567-582.[4]KUSTERS J G, NIESTERS H G M, BLEUMINK-PLUYM N M C, et al. Molecular epidemiology of infectious bronchitis virus in the Netherlands[J]. Gen Virol, 1987, 68: 343-352.[5]WANG L, JUNKER D, COLLISSON E W. Evidence of natural recombination within the S1 gene of infectious bronchitis virus[J]. Virology, 1993, 192: 710-716.[6]YANG Z Y, KONG W P, HUANG Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice[J]. Nature, 2004, 428: 561-564.[7]STOHLMAN S A, KYUWA S, COHEN M, et al. Mouse hepatitis virus nucleocapsid protein-specific cytotoxic T lymphocytes are Ld restricted and specific for the carboxy terminus[J]. Virology, 1992, 189(1): 217-224.[8]WEBSTER D P, DUNACHIE S, VUOLA J M, et al. Enhanced T cell mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara[J]. PNAS, 2005, 102(13): 4836-4842.[9]WEISS S R, NAVAS-MARTIN S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J]. Microbiol Mol Biol Rev, 2005, 69: 635-664.[10]BINNS M M, BOURSWELL M E, CAVANAGH D, et al. Cloning and sequencing of the gene encoding the spike protein of the coronavirus IBV[J]. Gen Virol, 1985, 66: 719-726.[11]KWON H M, JACKWOOD M W. Molecular cloning and sequence comparison of the S1 glycoprotein of the Gray and JMK strains of avian infectious bronchitis virus[J]. Virus Genes, 1995, 9: 219-229.[12]TOMLEY F M, MOCKETT A P, BOURSNELL M E, et al. Expression of the infectious bronchitis virus spike protein by recombinant vaccinia virus and induction of neutralizing antibodies in vaccinated mice[J]. Gen Virol, 1987, 68: 2291-2298.[13]WANG X, SCHNITZLEIN W M, TRIPATHY D N, et al. Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus[J]. Avian Dis, 2002, 46: 831-838.[14]JOHNSON M A, POOLEY C, IGNJATOVIC J, et al. A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus[J]. Vaccine, 2003, 21: 2730-2736.[15]CAVANAGH D, NAQI S. Infectious bronchitis virus[M]//CALNEK B W, BARNES H J, BEARD C W, et al. Disease of Poultry. 9th ed. Ames, IA: Iowa State University Press, 1997: 511-526.[16]RUSSELL W C. Update on adenovirus and its vectors[J]. Gen Virol, 2000, 81: 2573-2604.[17]YAROSH O K, WANDEL A I, GRAHAM F L, et al. Human adenovirus types vectors expressing rabies glycoprotein[J]. Vaccine, 1996, 14(13): 1257-1264.[18]XIANG Z Q, YANG Y P, WILSON J M, et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier[J]. Virol, 1996, 219: 220-227.[19]PREVEC L, COMPBELL J B, CHRISTIE B S, et al. A recombinant human adenovirus vaccine against rabies[J]. Infect Dis, 1990, 161: 27-33. |